Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

FDA funds Yale work to promote trials diversity

The FDA has awarded a $3 million contract to Yale School of Medicine to promote clinical trial education, awareness, and access for underrepresented minorities. The...

| By Kelley Gipson

CytoVeris awarded SBIR grant re bladder cancer

CytoVeris reports that the company has been awarded a National Cancer Institute Small Business Innovation Research (SBIR) Grant from the National Institute of Health (NIH)...

| By Kelley Gipson

Cybrexa sees efficacy signals in tumor targeting

Cybrexa Therapeutics reports favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex™-exatecan). The initial data show robust efficacy signals and tolerability in...

| By Kelley Gipson

Biorez wins patents for BioBrace implants

New Haven medtech Biorez has won four new patents for its BioBrace implant, a tissue scaffold that aims to speed healing in knee and rotator...

| By Kelley Gipson

BioXcel expands trial of prostate cancer drug

New Haven-based BioXcel Therapeutics is expanding its Phase 2 trial of BXCL701, its drug candidate for prostate cancer. BXCL701 is the company’s investigational, orally administered...

| By Kelley Gipson

NIH awards $8M to Guilford’s Detect re COVID tests

The National Institutes of Health has awarded Guilford-based biotech Detect $8.1 million to scale up manufacturing of its COVID-19 test. Detect, founded by serial entrepreneur...

| By Kelley Gipson

Hamden medtech CoRISMA raises capital

Hong Kong-based China Grand Pharmaceutical and Healthcare Holdings has invested $27 million in the Hamden-based company CoRISMA MCS Systems. The early-stage medical device startup will use the...

| By Kelley Gipson

Ghana FDA approves Vanessa for antidiarrheal trials

Vanessa Biotech has been granted regulatory approval from the Ghana FDA to conduct Phase 2 clinical trials for VR-AD-1005, a novel antidiarrheal investigational drug. The Phase...

| By Kelley Gipson

New Haven bio poised for boom, leaders say

Bioscience leaders outlined the challenges of bringing their discoveries to market and growing in New Haven as part of a panel discussion with public officials...